Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, 435 East 30th Street, New York, NY 10016, USA; Institute for Systems Genetics, NYU Grossman School of Medicine, 435 East 30th Street, New York, NY 10016, USA
Marcus Noyes
Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, 435 East 30th Street, New York, NY 10016, USA; Institute for Systems Genetics, NYU Grossman School of Medicine, 435 East 30th Street, New York, NY 10016, USA; Corresponding author
The discovery of regulatory domains has been limited to the investigation of transcription factors and homologous protein sequences. In this issue of Cell Genomics, motivated by an oncogenic protein fusion, Tak et al.1 direct the regulatory potential of a nontraditional effector domain to novel genomic loci with fusions to programmable DNA-binding domains.
